Amgen, Inc. has doubled the leadership of its research and development efforts, announcing on 14 December that it recruited former Novartis Institutes for BioMedical Research Inc. (NIBR) president Jay Bradner to serve as executive vice president of R&D and chief scientific officer. Current EVP of R&D David Reese remains in the company’s C-suite as executive vice president and chief technology officer.
Bradner’s addition to Amgen’s leadership team comes at a crucial time for the company as it continues to work its way through several big losses of exclusivity for past blockbusters such as Neulasta (pegfilgrastim) and anticipates LOEs later in this decade for additional top sellers, like Prolia (denosumab), while launching multiple new products, including asthma therapy Tezspire (tezepelumab) and KRAS G12C inhibitor Lumakras (sotorasib) for lung cancer. R&D output is a major focus for Amgen as it aims to grow revenue going forward
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?